Antibodies and polypeptides directed against CD127

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11926671
SERIAL NO

17363260

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • OSE IMMUNOTHERAPEUTICS

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Mary, Caroline Sainte-Pazanne, FR 34 62
Poirier, Nicolas Treillieres, FR 43 73
Thepenier, Virginie Sainte-Pazanne, FR 11 9
Vanhove, Bernard Reze, FR 37 209

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 12, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 12, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 12, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00